Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:XLRN
- CUSIP: N/A
- Web: www.acceleronpharma.com
Capitalization:- Market Cap: $1.21454 billion
- Outstanding Shares: 38,617,000
Average Prices:- 50 Day Moving Avg: $30.73
- 200 Day Moving Avg: $28.06
- 52 Week Range: $23.07 - $41.69
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.48
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $13.27 million
- Price / Sales: 91.52
- Book Value: $5.40 per share
- Price / Book: 5.82
Profitability:- EBIDTA: ($86,120,000.00)
- Net Margins: -659.04%
- Return on Equity: -38.57%
- Return on Assets: -34.51%
Debt:- Current Ratio: 9.81%
- Quick Ratio: 9.81%
Misc:- Average Volume: 385,622 shs.
- Beta: 1.71
- Short Ratio: 9.74
Frequently Asked Questions for Acceleron Pharma (NASDAQ:XLRN)
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc. (NASDAQ:XLRN) released its earnings results on Monday, May, 8th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.08. The company earned $3.71 million during the quarter, compared to analyst estimates of $3.38 million. Acceleron Pharma had a negative return on equity of 38.57% and a negative net margin of 659.04%. The firm's revenue for the quarter was down 79.6% on a year-over-year basis. During the same quarter last year, the business earned $0.13 earnings per share. View Acceleron Pharma's Earnings History.
When will Acceleron Pharma make its next earnings announcement?
Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2017?
15 brokers have issued twelve-month price targets for Acceleron Pharma's stock. Their forecasts range from $20.00 to $63.00. On average, they expect Acceleron Pharma's stock price to reach $42.54 in the next year. View Analyst Ratings for Acceleron Pharma.
What are analysts saying about Acceleron Pharma stock?
Here are some recent quotes from research analysts about Acceleron Pharma stock:
- 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (7/13/2017)
- 2. Cann analysts commented, "Acceleron Pharma announced today that updated preliminary results from phase II studies of Luspatercept in beta-thalassemia were released at the 22nd Congress of the European Hematology Association. It was reported that results from this ongoing study demonstrate increases in hemoglobin and decreases in red blood cell transfusion burden sustained for up to 24 months, with patients still active on treatment. These data presented today are very encouraging and appear to be as good as or better than data previously presented for Luspatercept." (6/23/2017)
- 3. Instinet analysts commented, "We are initiating coverage of Acceleron (XLRN) with a Buy rating and $58 target price. We recommend owning XLRN shares ahead of what we view as underappreciated 2H17 readouts. We foresee upside to the shares following positive results in 2H17 from a Phase 2 study of ACE-083, a myostatin+ inhibitor in FSHD. ACE-083 is a wholly owned program that is not currently ascribed value in XLRN's share price but worth $19/sh, by our estimate. We believe that these near-term data have been obscured by investors' focus on pivotal 2H18 Phase 3 results from Celgene-partnered (20-25% royalties) blockbuster luspatercept in MDS and beta-thalassemia. We expect further share price appreciation from this program in 2H17, as Phase 2 extension data for luspatercept better frames the magnitude of, and potential upside to, the market opportunity from indication expansion in myeloid diseases outside beta-thalassemia and MDS." (3/1/2017)
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Sarepta Therapeutics (SRPT), AveXis (AVXS), Axovant Sciences (AXON), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Dermira (DERM), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP) and Omeros Corporation (OMER).
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Francois E. Nader M.D., Independent Chairman of the Board
- Habib J. Dable, President, Chief Executive Officer, Director
- Kevin F. McLaughlin, Chief Financial Officer, Senior Vice President, Treasurer
- Matthew L. Sherman M.D., Executive Vice President and Chief Medical Officer
- Ravindra Kumar Ph.D, Senior Vice President, Chief Scientific Officer
- John D. Quisel J.D., Ph.D., Senior Vice President, Business Development, General Counsel and Secretary
- Jean M. George, Independent Director
- George S. Golumbeski Ph.D., Independent Director
- Terrence C. Kearney, Independent Director
- Tom Maniatis Ph.D., Independent Director
Who owns Acceleron Pharma stock?
Acceleron Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Verde Servicos Internacionais S.A. (0.06%), Fox Run Management L.L.C. (0.04%) and Bank of Montreal Can (0.02%). Company insiders that own Acceleron Pharma stock include Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.
Who sold Acceleron Pharma stock? Who is selling Acceleron Pharma stock?
Acceleron Pharma's stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have sold Acceleron Pharma stock in the last year include Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Insider Buying and Selling for Acceleron Pharma.
How do I buy Acceleron Pharma stock?
Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of Acceleron Pharma stock can currently be purchased for approximately $31.45.
MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 4 Hold Ratings, 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $42.54 (35.26% upside) |
Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/4/2017 | Credit Suisse Group | Reiterated Rating | Buy | $46.00 | Medium |  |
| 6/26/2017 | Piper Jaffray Companies | Boost Price Target | Overweight | $32.00 -> $40.00 | High | |
| 6/23/2017 | Cann | Reiterated Rating | Neutral -> Hold | | High | |
| 6/14/2017 | Instinet | Reiterated Rating | Buy | $58.00 | Low | |
| 6/13/2017 | FBR & Co | Set Price Target | Buy | $63.00 | High | |
| 6/13/2017 | Morgan Stanley | Lower Price Target | Overweight | $51.00 -> $42.00 | High | |
| 6/13/2017 | CIBC | Downgrade | Outperform -> Market Perform | | Low | |
| 6/13/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform -> Market Perform | | High | |
| 5/17/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Sell -> Sell | $20.00 | High | |
| 5/1/2017 | JMP Securities | Reiterated Rating | Outperform | $39.00 | Low | |
| 3/14/2017 | J P Morgan Chase & Co | Initiated Coverage | Neutral -> Neutral | $33.00 | High | |
| 3/2/2017 | Citigroup Inc. | Upgrade | Neutral -> Buy | $40.00 -> $36.00 | N/A | |
| 3/1/2017 | Nomura | Initiated Coverage | Buy | | N/A | |
| 12/1/2016 | Leerink Swann | Set Price Target | Buy | $50.00 | N/A | |
| 8/19/2016 | BTIG Research | Initiated Coverage | Buy | $46.00 | N/A | |
| 6/13/2016 | Barclays PLC | Boost Price Target | Overweight | $40.00 -> $42.00 | N/A | |
| 2/29/2016 | Janney Montgomery Scott | Upgrade | Neutral -> Buy | $45.00 -> $39.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for Acceleron Pharma (NASDAQ:XLRN)Earnings History by Quarter for Acceleron Pharma (NASDAQ XLRN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | ($0.63) | | | | | N/A | |
| 5/8/2017 | 3/31/2017 | ($0.58) | ($0.66) | $3.38 million | $3.71 million | View | Listen | |
| 3/1/2017 | Q416 | ($0.55) | ($0.51) | $3.74 million | $3.37 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.53) | ($0.55) | $4.08 million | $3.00 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.50) | ($0.59) | $3.77 million | $3.20 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.26) | $0.14 | $8.70 million | $18.20 million | View | Listen | |
| 2/25/2016 | Q415 | ($0.09) | ($0.81) | $15.70 million | $3.80 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.46) | ($0.36) | $4.38 million | $4.16 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.49) | ($0.32) | $4.23 million | $5.72 million | View | Listen | |
| 5/7/2015 | | ($0.43) | ($0.45) | $3.98 million | $4.42 million | View | N/A | |
| 3/2/2015 | Q414 | ($0.23) | ($0.55) | $12.90 million | $3.74 million | View | Listen | |
| 11/7/2014 | | ($0.27) | ($0.25) | $17.76 million | $3.51 million | View | N/A | |
| 8/12/2014 | | ($0.55) | ($0.54) | | $4.08 million | View | N/A | |
| 5/15/2014 | Q114 | ($0.44) | ($0.30) | $2.85 million | $3.31 million | View | N/A | |
| 2/26/2014 | Q413 | ($0.08) | ($0.64) | $13.66 million | $11.50 million | View | N/A | |
| 11/6/2013 | | ($0.19) | ($5.62) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)2017 EPS Consensus Estimate: ($2.53)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.62) | ($0.51) | ($0.57) |
| Q2 2017 | 3 | ($0.69) | ($0.62) | ($0.66) |
| Q3 2017 | 3 | ($0.71) | ($0.54) | ($0.64) |
| Q4 2017 | 3 | ($0.75) | ($0.53) | ($0.66) |
(Data provided by Zacks Investment Research)
Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Acceleron Pharma (NASDAQ:XLRN)Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 83.54%
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Kevin F Mclaughlin | CFO | Sell | 34,400 | $32.00 | $1,100,800.00 | |
| 7/5/2017 | Matthew L Sherman | EVP | Sell | 16,000 | $32.00 | $512,000.00 | |
| 7/5/2017 | Ravindra Kumar | SVP | Sell | 937 | $32.00 | $29,984.00 | |
| 1/4/2017 | Kevin F Mclaughlin | CFO | Sell | 1,700 | $27.45 | $46,665.00 | |
| 1/4/2017 | Matthew L Sherman | EVP | Sell | 2,000 | $27.46 | $54,920.00 | |
| 1/4/2017 | Steven D Ertel | COO | Sell | 2,500 | $27.44 | $68,600.00 | |
| 12/30/2016 | Joseph S Zakrzewski | Director | Buy | 4,000 | $25.50 | $102,000.00 | |
| 12/8/2016 | Terrance Mcguire | Director | Sell | 34,928 | $30.96 | $1,081,370.88 | |
| 11/17/2016 | Jean George | Director | Sell | 453,505 | $38.39 | $17,410,056.95 | |
| 10/10/2016 | Ravindra Kumar | SVP | Sell | 52,486 | $33.92 | $1,780,325.12 | |
| 9/30/2016 | Jean George | Director | Sell | 857,145 | $35.50 | $30,428,647.50 | |
| 9/21/2016 | John D Quisel | SVP | Sell | 45,952 | $38.05 | $1,748,473.60 | |
| 9/12/2016 | John D Quisel | SVP | Sell | 21,438 | $32.14 | $689,017.32 | |
| 7/6/2016 | John L Knopf | CEO | Sell | 100,000 | $33.87 | $3,387,000.00 | |
| 7/5/2016 | John L Knopf | CEO | Sell | 30,501 | $33.26 | $1,014,463.26 | |
| 7/5/2016 | Steven D Ertel | COO | Sell | 32,270 | $34.56 | $1,115,251.20 | |
| 7/1/2016 | John L Knopf | CEO | Sell | 28,022 | $34.72 | $972,923.84 | |
| 7/1/2016 | Kevin F Mclaughlin | CFO | Sell | 25,300 | $34.66 | $876,898.00 | |
| 7/1/2016 | Matthew L Sherman | EVP | Sell | 26,000 | $34.74 | $903,240.00 | |
| 7/1/2016 | Steven D Ertel | COO | Sell | 28,304 | $34.77 | $984,130.08 | |
| 5/20/2016 | John L Knopf | CEO | Sell | 100,000 | $33.07 | $3,307,000.00 | |
| 4/7/2016 | Matthew L Sherman | EVP | Sell | 26,000 | $32.00 | $832,000.00 | |
| 4/7/2016 | Steven D Ertel | COO | Sell | 32,270 | $32.00 | $1,032,640.00 | |
| 1/11/2016 | Corp /De/ Celgene | Major Shareholder | Buy | 800,000 | $40.00 | $32,000,000.00 | |
| 10/15/2015 | Matthew L. Sherman | EVP | Sell | 6,000 | $23.28 | $139,680.00 | |
| 10/7/2015 | John L. Knopf | CEO | Sell | 19,000 | $24.38 | $463,220.00 | |
| 10/7/2015 | Kevin F. Mclaughlin | CFO | Sell | 7,000 | $24.38 | $170,660.00 | |
| 9/16/2015 | Matthew L. Sherman | EVP | Sell | 2,000 | $33.24 | $66,480.00 | |
| 9/15/2015 | Ravindra Kumar | VP | Sell | 33,000 | $35.00 | $1,155,000.00 | |
| 9/15/2015 | Steven D. Ertel | COO | Sell | 2,000 | $33.61 | $67,220.00 | |
| 9/14/2015 | John D. Quisel | SVP | Sell | 5,500 | $33.35 | $183,425.00 | |
| 9/8/2015 | John L. Knopf | CEO | Sell | 19,000 | $30.20 | $573,800.00 | |
| 9/8/2015 | Kevin F. Mclaughlin | CFO | Sell | 6,500 | $30.16 | $196,040.00 | |
| 8/18/2015 | Matthew L Sherman | EVP | Sell | 7,000 | $31.13 | $217,910.00 | |
| 8/14/2015 | John D Quisel | SVP | Sell | 5,500 | $30.83 | $169,565.00 | |
| 7/20/2015 | Matthew L Sherman | EVP | Sell | 6,000 | $32.46 | $194,760.00 | |
| 7/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $31.38 | $62,760.00 | |
| 7/14/2015 | John D Quisel | SVP | Sell | 5,500 | $30.00 | $165,000.00 | |
| 7/7/2015 | John L Knopf | CEO | Sell | 19,000 | $29.70 | $564,300.00 | |
| 7/7/2015 | Kevin F Mclaughlin | CFO | Sell | 7,000 | $29.70 | $207,900.00 | |
| 6/18/2015 | Matthew L Sherman | EVP | Sell | 7,000 | $31.54 | $220,780.00 | |
| 6/15/2015 | John D Quisel | SVP | Sell | 5,500 | $31.13 | $171,215.00 | |
| 6/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $31.11 | $62,220.00 | |
| 6/8/2015 | John L Knopf | CEO | Sell | 19,000 | $32.51 | $617,690.00 | |
| 6/8/2015 | Kevin F Mclaughlin | CFO | Sell | 6,500 | $32.49 | $211,185.00 | |
| 5/18/2015 | Matthew L Sherman | EVP | Sell | 7,000 | $32.37 | $226,590.00 | |
| 5/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $31.49 | $62,980.00 | |
| 4/20/2015 | Matthew L Sherman | EVP | Sell | 5,000 | $33.52 | $167,600.00 | |
| 4/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $33.58 | $67,160.00 | |
| 4/7/2015 | John L Knopf | CEO | Sell | 20,000 | $34.87 | $697,400.00 | |
| 4/7/2015 | Kevin F Mclaughlin | CFO | Sell | 7,000 | $34.88 | $244,160.00 | |
| 3/18/2015 | Matthew L Sherman | EVP | Sell | 6,000 | $41.18 | $247,080.00 | |
| 3/16/2015 | John D Quisel | SVP | Sell | 9,500 | $41.00 | $389,500.00 | |
| 3/9/2015 | John L Knopf | CEO | Sell | 20,000 | $40.25 | $805,000.00 | |
| 3/9/2015 | Kevin F Mclaughlin | CFO | Sell | 6,500 | $40.25 | $261,625.00 | |
| 1/20/2015 | Matthew L Sherman | SVP | Sell | 7,000 | $41.64 | $291,480.00 | |
| 1/15/2015 | Steven D Ertel | SVP | Sell | 2,000 | $40.58 | $81,160.00 | |
| 1/12/2015 | Kevin F Mclaughlin | CFO | Sell | 2,000 | $40.66 | $81,320.00 | |
| 1/12/2015 | Ravindra Kumar | VP | Sell | 1,500 | $40.80 | $61,200.00 | |
| 1/7/2015 | John L Knopf | CEO | Sell | 20,000 | $39.62 | $792,400.00 | |
| 1/7/2015 | Kevin F Mclaughlin | CFO | Sell | 5,000 | $39.46 | $197,300.00 | |
| 1/2/2015 | Ravindra Kumar | VP | Sell | 4,000 | $38.46 | $153,840.00 | |
| 1/2/2015 | Steven D Ertel | SVP | Sell | 5,000 | $38.47 | $192,350.00 | |
| 12/23/2014 | Edwin M Kania Jr | Director | Sell | 54,350 | $38.00 | $2,065,300.00 | |
| 12/18/2014 | Matthew L Sherman | SVP | Sell | 5,000 | $40.16 | $200,800.00 | |
| 12/12/2014 | John D Quisel | SVP | Sell | 4,000 | $41.35 | $165,400.00 | |
| 12/9/2014 | Jean George | Director | Sell | 97,407 | $44.90 | $4,373,574.30 | |
| 12/8/2014 | John L Knopf | CEO | Sell | 20,000 | $43.99 | $879,800.00 | |
| 12/8/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $44.02 | $440,200.00 | |
| 12/8/2014 | Tom Maniatis | Director | Sell | 23,400 | $45.00 | $1,053,000.00 | |
| 12/1/2014 | Ravindra Kumar | VP | Sell | 4,000 | $35.88 | $143,520.00 | |
| 12/1/2014 | Steven D Ertel | SVP | Sell | 7,500 | $35.87 | $269,025.00 | |
| 11/18/2014 | Matthew L Sherman | SVP | Sell | 5,082 | $33.76 | $171,568.32 | |
| 11/13/2014 | Ravindra Kumar | VP | Sell | 16,000 | $34.53 | $552,480.00 | |
| 10/28/2014 | Tom Maniatis | Director | Sell | 23,400 | $35.00 | $819,000.00 | |
| 10/8/2014 | John L Knopf | CEO | Sell | 20,000 | $29.71 | $594,200.00 | |
| 10/8/2014 | Matthew L Sherman | SVP | Sell | 5,082 | $29.50 | $149,919.00 | |
| 10/7/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $29.25 | $292,500.00 | |
| 10/1/2014 | Ravindra Kumar | VP | Sell | 11,000 | $29.89 | $328,790.00 | |
| 10/1/2014 | Steven D Ertel | SVP | Sell | 10,000 | $29.66 | $296,600.00 | |
| 9/30/2014 | John D Quisel | SVP | Sell | 7,000 | $30.01 | $210,070.00 | |
| 9/18/2014 | Matthew L Sherman | SVP | Sell | 5,000 | $25.48 | $127,400.00 | |
| 9/12/2014 | John D Quisel | SVP | Sell | 2,000 | $25.43 | $50,860.00 | |
| 9/9/2014 | John L Knopf | CEO | Sell | 20,000 | $24.46 | $489,200.00 | |
| 9/9/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $24.48 | $244,800.00 | |
| 9/8/2014 | John L Knopf | CEO | Sell | 6,700 | $24.92 | $166,964.00 | |
| 9/8/2014 | Kevin F Mclaughlin | CFO | Sell | 3,300 | $24.90 | $82,170.00 | |
| 9/3/2014 | Matthew L Sherman | SVP | Sell | 5,000 | $25.82 | $129,100.00 | |
| 8/18/2014 | Matthew L Sherman | SVP | Sell | 2,500 | $29.62 | $74,050.00 | |
| 8/14/2014 | John D Quisel | SVP | Sell | 13,000 | $29.98 | $389,740.00 | |
| 8/14/2014 | John L Knopf | CEO | Sell | 17,500 | $29.78 | $521,150.00 | |
| 8/14/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $29.78 | $297,800.00 | |
| 8/14/2014 | Ravindra Kumar | VP | Sell | 9,000 | $29.97 | $269,730.00 | |
| 7/18/2014 | Matthew L Sherman | SVP | Sell | 2,500 | $26.22 | $65,550.00 | |
| 7/14/2014 | John D Quisel | SVP | Sell | 5,000 | $29.73 | $148,650.00 | |
| 7/9/2014 | Matthew L Sherman | SVP | Sell | 7,500 | $28.99 | $217,425.00 | |
| 7/7/2014 | John L Knopf | CEO | Sell | 17,500 | $31.74 | $555,450.00 | |
| 7/7/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $31.72 | $317,200.00 | |
| 7/1/2014 | Ravindra Kumar | VP | Sell | 2,000 | $34.10 | $68,200.00 | |
| 7/1/2014 | Steven D Ertel | SVP | Sell | 10,000 | $34.09 | $340,900.00 | |
| 6/26/2014 | Jean George | Director | Sell | 10,491 | $35.01 | $367,289.91 | |
| 6/24/2014 | Jean George | Director | Sell | 25,477 | $35.16 | $895,771.32 | |
| 6/20/2014 | Ravindra Kumar | VP | Sell | 7,000 | $35.00 | $245,000.00 | |
| 6/18/2014 | Matthew L Sherman | SVP | Sell | 2,500 | $34.42 | $86,050.00 | |
| 6/13/2014 | John D Quisel | VP | Sell | 9,000 | $33.94 | $305,460.00 | |
| 6/11/2014 | Matthew L Sherman | SVP | Sell | 7,500 | $33.23 | $249,225.00 | |
| 6/9/2014 | John L Knopf | CEO | Sell | 15,000 | $31.65 | $474,750.00 | |
| 6/9/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $31.65 | $316,500.00 | |
| 5/19/2014 | John Knopf | CEO | Sell | 15,000 | $31.52 | $472,800.00 | |
| 5/19/2014 | John Quisel | VP | Sell | 9,000 | $31.43 | $282,870.00 | |
| 5/19/2014 | Steven Ertel | SVP | Sell | 10,000 | $31.52 | $315,200.00 | |
| 5/5/2014 | Corp /De/ Celgene | major shareholder | Buy | 1,100,000 | $42.86 | $47,146,000.00 | |
| 5/5/2014 | Jean George | Director | Sell | 215,644 | $42.86 | $9,242,501.84 | |
| 4/24/2014 | Edwin Kania, Jr. | Director | Sell | 1,000,000 | $32.05 | $32,050,000.00 | |
| 4/22/2014 | Ravindra Kumar | VP | Sell | 2,000 | $35.86 | $71,720.00 | |
| 4/22/2014 | Steven Ertel | SVP | Sell | 2,500 | $35.87 | $89,675.00 | |
| 1/28/2014 | Corp /De/ Celgene | Major Shareholder | Buy | 300,000 | $50.00 | $15,000,000.00 | |
| 9/24/2013 | Corp /De/ Celgene | Major Shareholder | Buy | 666,667 | $15.00 | $10,000,005.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Acceleron Pharma (NASDAQ:XLRN)
Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Brokerages Anticipate Acceleron Pharma Inc. (NASDAQ:XLRN) to Announce -$0.66 Earnings Per Share
www.americanbankingnews.com - July 21 at 9:48 AM |
| Acceleron Pharma Inc. (XLRN) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - July 13 at 1:04 PM |
| Acceleron Pharma Inc. (NASDAQ:XLRN) SVP Sells $29,984.00 in Stock
www.americanbankingnews.com - July 7 at 9:02 PM |
| Acceleron Pharma Inc. (XLRN) EVP Sells $512,000.00 in Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
| Acceleron Pharma Inc. (XLRN) CFO Sells $1,100,800.00 in Stock
www.americanbankingnews.com - July 7 at 7:57 PM |
| Acceleron Pharma Inc. (NASDAQ:XLRN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 4 at 11:06 AM |
| Zacks: Analysts Anticipate Acceleron Pharma Inc. (XLRN) Will Announce Quarterly Sales of $3.52 Million
www.americanbankingnews.com - June 28 at 9:51 AM |
| Acceleron Pharma Inc. (XLRN) Expected to Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - June 27 at 12:38 AM |
| Acceleron Pharma Inc. (XLRN) Price Target Increased to $40.00 by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - June 26 at 12:52 PM |
 | Acceleron Pharma (XLRN) Presents Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia
www.streetinsider.com - June 23 at 8:21 PM |
| Acceleron Pharma Inc. (XLRN) Given "Hold" Rating at Cann
www.americanbankingnews.com - June 23 at 11:34 AM |
 | Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association
finance.yahoo.com - June 23 at 6:06 AM |
| Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association
finance.yahoo.com - June 23 at 6:06 AM |
| Acceleron Pharma Inc. (XLRN) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - June 21 at 3:10 PM |
| Acceleron Pharma Inc. (XLRN) Downgraded to Market Perform at CIBC
www.americanbankingnews.com - June 18 at 4:58 PM |
| Acceleron Pharma Inc. (XLRN) Price Target Cut to $42.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - June 18 at 4:20 PM |
| Acceleron Pharma Inc. (XLRN) Given a $63.00 Price Target at FBR & Co
www.americanbankingnews.com - June 18 at 3:02 PM |
| Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
finance.yahoo.com - June 15 at 4:12 PM |
| Oppenheimer Holdings Weighs in on Acceleron Pharma Inc.'s Q2 2017 Earnings (XLRN)
www.americanbankingnews.com - June 15 at 7:38 AM |
| Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II
finance.yahoo.com - June 14 at 4:17 PM |
| Acceleron Pharma Inc. (XLRN) Receives "Buy" Rating from Instinet
www.americanbankingnews.com - June 14 at 9:44 AM |
| Acceleron: When Bad News Is Really Good News
finance.yahoo.com - June 14 at 2:23 AM |
| Acceleron investors react to trial flop with a shrug, then cheers
finance.yahoo.com - June 14 at 2:23 AM |
| Can This Small Biotech Be Saved By Developing Anemia Drug?
finance.yahoo.com - June 14 at 2:23 AM |
| Oppenheimer Holdings, Inc. Reiterates Market Perform Rating for Acceleron Pharma Inc. (XLRN)
www.americanbankingnews.com - June 13 at 9:04 AM |
| Acceleron Pharma (XLRN) Says DART Phase 2 Study of Dalantercept in RCC Didn't Met Primary Endpoint
www.streetinsider.com - June 12 at 8:12 PM |
 | Acceleron Pharma Inc. (XLRN) Is Falling After Phase 2 Study Failed
www.rttnews.com - June 12 at 8:12 PM |
| Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma
finance.yahoo.com - June 12 at 8:12 PM |
| Acceleron Pharma Inc (XLRN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 9 at 10:58 AM |
 | Acceleron Pharma (XLRN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 2:48 AM |
| ETFs with exposure to Acceleron Pharma, Inc. : June 5, 2017
finance.yahoo.com - June 6 at 2:54 AM |
| Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : June 5, 2017
finance.yahoo.com - June 5 at 9:35 AM |
| $3.52 Million in Sales Expected for Acceleron Pharma Inc (XLRN) This Quarter
www.americanbankingnews.com - June 2 at 11:40 AM |
| Cann Reaffirms "Buy" Rating for Acceleron Pharma Inc (XLRN)
www.americanbankingnews.com - June 1 at 11:10 AM |
| -$0.66 Earnings Per Share Expected for Acceleron Pharma Inc (XLRN) This Quarter
www.americanbankingnews.com - May 31 at 10:30 PM |
| Acceleron Pharma (XLRN) Presents At UBS Global Healthcare Conference 2017 - Slideshow
seekingalpha.com - May 23 at 8:11 PM |
| Acceleron Pharma Inc (XLRN) Given Buy Rating at FBR & Co
www.americanbankingnews.com - May 19 at 7:16 PM |
| Acceleron Pharma (XLRN) Announces Clinical Presentations on Luspatercept at EHA
www.streetinsider.com - May 18 at 8:50 AM |
| Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association
finance.yahoo.com - May 18 at 8:50 AM |
| Acceleron Pharma Inc (XLRN) Coverage Initiated by Analysts at Goldman Sachs Group Inc
www.americanbankingnews.com - May 17 at 11:38 PM |
| Acceleron Pharma Inc (XLRN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 15 at 12:04 PM |
| Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : May 11, 2017
finance.yahoo.com - May 11 at 8:22 PM |
| Acceleron Pharma Inc (XLRN) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - May 11 at 1:06 PM |
| Q2 2017 EPS Estimates for Acceleron Pharma Inc Lowered by Analyst (XLRN)
www.americanbankingnews.com - May 11 at 8:07 AM |
| Leerink Swann Weighs in on Acceleron Pharma Inc's Q2 2017 Earnings (XLRN)
www.americanbankingnews.com - May 11 at 7:34 AM |
| Acceleron Pharma Inc (XLRN) Expected to Post Q2 2017 Earnings of ($0.69) Per Share
www.americanbankingnews.com - May 10 at 7:50 AM |
| FBR & Co Weighs in on Acceleron Pharma Inc's FY2019 Earnings (XLRN)
www.americanbankingnews.com - May 9 at 11:52 AM |
| Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : May 9, 2017
finance.yahoo.com - May 9 at 9:33 AM |
| Edited Transcript of XLRN earnings conference call or presentation 8-May-17 12:00pm GMT
finance.yahoo.com - May 8 at 8:14 PM |
| How Celgene Toppled On A Small-Cap Biotech's Ragged Quarter
finance.yahoo.com - May 8 at 8:14 PM |
Acceleron Pharma (XLRN) Chart for Sunday, July, 23, 2017
